We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ambrx Biopharma Inc | NASDAQ:AMAM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 28.00 | 27.92 | 25.00 | 0 | 01:00:00 |
From Nov 2023 to May 2024
By Ben Glickman
Shares of Ambrx Biopharma surged Monday after the company agreed to be acquired by Johnson & Johnson for $2 billion in cash.
The stock was up 98% to $27.05 in morning trading. Shares have risen sixfold in the last year.
Johnson & Johnson will pay $28 a share, which Ambrx said represented a premium of 105% on the Jan. 5 closing price.
The deal is expected to have a value of $1.9 billion net of estimated cash required.
Ambryx is developing candidates for treating multiple types of cancer using a proprietary synthetic biotechnology platform.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 08, 2024 09:49 ET (14:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Ambrx Biopharma Chart |
1 Month Ambrx Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
